Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 1/2010

01-02-2010

Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment

Author: Robert S. Rosenson

Published in: Cardiovascular Drugs and Therapy | Issue 1/2010

Login to get access

Excerpt

Residual cardiovascular risk associated with low levels of HDL was a major theme at the American Heart Association’s 2009 Scientific Sessions. The presentations on HDL biology encompassed a broad spectrum of investigations that ranged from population-based studies, anti-atherothrombotic mechanisms of HDL particles, and therapeutic approaches to raising HDL cholesterol levels. This meeting highlight reviews some of the most important presentations that serve to enhance our knowledge in areas that extend beyond measurement of HDL cholesterol or apolipoprotein A-I concentration to precise mechanisms that elucidate functional aspects of HDL particles. …
Literature
1.
go back to reference Mora S, Cui Y, Ridker PM. Association of HDL cholesterol and apolipoprotein A-I with incident CVD across levels of LDL cholesterol in 27, 748 women. Circulation. 2009;120:S507.CrossRef Mora S, Cui Y, Ridker PM. Association of HDL cholesterol and apolipoprotein A-I with incident CVD across levels of LDL cholesterol in 27, 748 women. Circulation. 2009;120:S507.CrossRef
2.
go back to reference Frikke-Schmidt R et al. Cholesterol ester transfer protein genotype predicts anti-atherogenic lipid profile and decreased risk of ischemic heart disease, ischemic cerebrovascular disease, and death not attributable to HDL cholesterol alone. Circulation. 2009;120:S1175. Frikke-Schmidt R et al. Cholesterol ester transfer protein genotype predicts anti-atherogenic lipid profile and decreased risk of ischemic heart disease, ischemic cerebrovascular disease, and death not attributable to HDL cholesterol alone. Circulation. 2009;120:S1175.
3.
go back to reference Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.CrossRefPubMed Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.CrossRefPubMed
4.
go back to reference Vasquez E, Sethi AA, Sampson M, Remaly AT, Chaudry H. O Cannon III R. “Dysfunctional” high-density lipoprotein despite normal cholesterol content in sedentary obese women. Circulation. 2009;120:S470. Vasquez E, Sethi AA, Sampson M, Remaly AT, Chaudry H. O Cannon III R. “Dysfunctional” high-density lipoprotein despite normal cholesterol content in sedentary obese women. Circulation. 2009;120:S470.
5.
go back to reference Khera AV, Rodriques A, de la Lioera-Moya M, Rothblatt GH, Rader DJ. Serum cholesterol efflux capacity, a measure of HDL-C quality, varies according to coronary artery disease status independently of HDL-C quantity. Circulation. 2009;120:S469. Khera AV, Rodriques A, de la Lioera-Moya M, Rothblatt GH, Rader DJ. Serum cholesterol efflux capacity, a measure of HDL-C quality, varies according to coronary artery disease status independently of HDL-C quantity. Circulation. 2009;120:S469.
6.
go back to reference Hara T, Ishida T, Kojima Y, Hirata K-I. Inactivation of endothelial lipase increases anti-inflammatory HDL particles. Circulation. 2009;120:S469. Hara T, Ishida T, Kojima Y, Hirata K-I. Inactivation of endothelial lipase increases anti-inflammatory HDL particles. Circulation. 2009;120:S469.
7.
go back to reference Besler C, Heinrich K, Rohrer L, Yonekawa K, Doerriers C, Manes C, et al. Mechanisms leading to impaired endothelial-vasoprotective properties of high density lipoprotein (HDL) in patients with coronary disease (CAD). Circulation. 2009;120:S1009. Besler C, Heinrich K, Rohrer L, Yonekawa K, Doerriers C, Manes C, et al. Mechanisms leading to impaired endothelial-vasoprotective properties of high density lipoprotein (HDL) in patients with coronary disease (CAD). Circulation. 2009;120:S1009.
8.
go back to reference Holy E, Stampfli SF, Akhmedov A, Camici G, Luscher TF, Tanner FC. High-density lipoprotein (HDL) from healthy subjects, but not from patients with coronary artery disease, exerts anti-thrombotic effects on human endothelial cells. Circulation. 2009;120:S1099.CrossRef Holy E, Stampfli SF, Akhmedov A, Camici G, Luscher TF, Tanner FC. High-density lipoprotein (HDL) from healthy subjects, but not from patients with coronary artery disease, exerts anti-thrombotic effects on human endothelial cells. Circulation. 2009;120:S1099.CrossRef
9.
go back to reference Drew BG, Duffy SJ, Forbes JM, Chin-Dusting J, Kaye DM, Kemp BE, et al. High density lipoprotein modulates glucose metabolism by multiple mechanisms. Circulation. 2009;120:S468. Drew BG, Duffy SJ, Forbes JM, Chin-Dusting J, Kaye DM, Kemp BE, et al. High density lipoprotein modulates glucose metabolism by multiple mechanisms. Circulation. 2009;120:S468.
10.
go back to reference Barter PJ, Caulfield M, Eriksson M, Griudy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.CrossRefPubMed Barter PJ, Caulfield M, Eriksson M, Griudy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.CrossRefPubMed
11.
go back to reference Stroes ESG, Kastelein JJP, Benardeau A, Kuhlmann O, Blum D, Campos LA, et al. B J Pharmacol. 2009;158:1763–70.CrossRef Stroes ESG, Kastelein JJP, Benardeau A, Kuhlmann O, Blum D, Campos LA, et al. B J Pharmacol. 2009;158:1763–70.CrossRef
12.
go back to reference Maugeais C, Magg C, Dernick G, Matile H, von der Mark E, Pflieger P, et al. Dalcetrapib binds to and changes the conformation of CETP in a unique manner (differing to that observed with torcetrapib). Circulation. 2009;120:S445.CrossRef Maugeais C, Magg C, Dernick G, Matile H, von der Mark E, Pflieger P, et al. Dalcetrapib binds to and changes the conformation of CETP in a unique manner (differing to that observed with torcetrapib). Circulation. 2009;120:S445.CrossRef
13.
go back to reference Niesor EJ, Okamoto H, Naugeais C, von der Mark E, Brousse M, Blum-Kaelin D, et al. The effects of dalcetrapib on macrophage reverse cholesterol transport in a rodent model. Circulation. 2009;120:S468. Niesor EJ, Okamoto H, Naugeais C, von der Mark E, Brousse M, Blum-Kaelin D, et al. The effects of dalcetrapib on macrophage reverse cholesterol transport in a rodent model. Circulation. 2009;120:S468.
14.
go back to reference Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)- 6-HDL and LDL treatment strategies in atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21:221–5.CrossRefPubMed Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)- 6-HDL and LDL treatment strategies in atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21:221–5.CrossRefPubMed
15.
go back to reference Taylor AJ, Villnes TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. N Engl J Med. 2009;361:2113–22.CrossRefPubMed Taylor AJ, Villnes TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. N Engl J Med. 2009;361:2113–22.CrossRefPubMed
Metadata
Title
Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment
Author
Robert S. Rosenson
Publication date
01-02-2010
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 1/2010
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-009-6214-3

Other articles of this Issue 1/2010

Cardiovascular Drugs and Therapy 1/2010 Go to the issue